Table 1. Baseline Characteristics.
| Characteristic | Patients (N = 156)a | |
|---|---|---|
| CT arm (n = 77) | MRI arm (n = 79) | |
| Age, median (IQR) | 71 (67-77) | 71 (68-75) |
| Risk group | ||
| Imaging N0b | ||
| Favorable intermediate | 15 (19) | 14 (18) |
| Unfavorable intermediate | 25 (32) | 40 (51) |
| High risk | 21 (27) | 15 (19) |
| Very high risk | 9 (12) | 5 (6) |
| Imaging N+b | 7 (9) | 5 (6) |
| Clinical T category 3 or 4b | 1 (1) | 4 (5) |
| Extracapsular extension on MRI | 21 (27) | 19 (25) |
| Seminal vesicle invasion on MRI | 11 (14) | 11 (14) |
| ADT use | 57 (74) | 49 (62) |
| Nodal radiation | 19 (25) | 18 (23) |
| GTV boost | 22 (29) | 19 (24) |
| Rectal spacer | 32 (42) | 37 (47) |
| Prior TURP or HOLEP | 3 (4) | 5 (6) |
| Prostate size, median (IQR), mL | 41 (33-59) | 39 (30-54) |
| IPSS, median (IQR) | 6.0 (3.0-11.0) | 7.0 (4.0-12.5) |
| Urinary medications at baseline | 27 (35) | 30 (38) |
| Baseline GI comorbidity | 18 (23) | 12 (15) |
| Hip replacement | 3 (4) | 6 (8) |
Abbreviations: ADT, androgen-deprivation therapy; CT, computed tomography; GI, gastrointestinal; GTV, gross tumor volume; HOLEP, holmium laser enucleation of the prostate; IPSS, International Prostate Symptom Score; MRI, magnetic resonance imaging; TURP, transurethral vapor resection of the prostate.
a
Data are presented as number (percentage) of patients unless otherwise indicated.
b
According to American Joint Committee on Cancer 8th edition criteria.